- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04472377
Agreement of hrHPV Type Between Self-collected Sample From Vaginal Fornix and Physician Collected Sample From the Cervical Surface
Evaluate the Agreement of High-risk Human Papillomavirus Type Between Self-collected Vaginal Discharge Sample Using "HygeiaTouch Self Sampling Kit for Woman" and Physician Collected Sample From the Cervix
Hygeia Touch Inc. developed a safe and comfortable vaginal self-sampling device "Hygeia Touch Self Sampling Kit for Women" to self-collect the vaginal discharge sample for high-risk Human Papillomavirus (hrHPV) detection.
This clinical trial aimed to evaluate the agreement of hrHPV detections between vaginal self-sampling using "Hygeia Touch Self Sampling Kit for Women" and physician sampling, and these results will be applied for TFDA registration approval.
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary end-point:
- Agreement of hr-HPV types, including types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, between the physician-collected sample and self-collected sample
- Agreement of the presence of hr-HPV between the physician-collected sample and self-collected sample
Secondary end-point:
- Percentage of the valid sample between self-collected and physician-collected specimens
- Agreement of all (N = 27) HPV types between the paired samples
- Adverse events associated with sample collection
- Questionnaire of the appreciation and satisfaction of using self-collecting vaginal discharge sample using "Hygeia Touch Self Sampling Kit for Women" through a short movie and a brief illustration
- Correlation between histological diagnosis and HPV types
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 833161
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Taoyuan, Taiwan, 33305
- Linkou Chang Gung Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Woman with a uterine cervix, i.e., with no previous total hysterectomy or radiotherapy for cervical tumor. The woman who received subtotal hysterectomy is allowed.
2. Signed informed consent. 3. Fit any one of the following conditions,
- with no history or current cervical intraepithelial lesion or malignancy.
- with a history of abnormal Pap test including atypical squamous cells of undetermined significance, cervical intraepithelial neoplasia grade 1, or atypical glandular cell.
- with a history of atypical squamous cells favor high-grade squamous intraepithelial lesion, dysplasia cannot exclude high-grade squamous intraepithelial lesion, cervical intraepithelial neoplasia grade 2, cervical intraepithelial neoplasia grade 3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.
- with current atypical squamous cells of undetermined significance, cervical intraepithelial neoplasia grade 1, or atypical glandular cell.
- with current abnormal Pap test as atypical squamous cells favor high-grade squamous intraepithelial lesion, dysplasia cannot exclude high-grade squamous intraepithelial lesion, cervical intraepithelial neoplasia grade 2, cervical intraepithelial neoplasia grade 3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.
Exclusion Criteria:
- History of total hysterectomy
- Pregnant
- Current cervicitis that requires therapy
- Received treatment for cervical lesion within 90 days
- Had undergone radiotherapy or is receiving radiation over the uterus, cervix or vagina
- Had sexual activity without a condom in 48 hours
- Excessive vaginal discharge, either in the ovulation period or due to inflammation
- is undergoing local therapy with an intravaginal tablet or residual drug in the vaginal canal
- during mense
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: study population
We enroll a total of 1,200 women, as follows,
|
A device to collect exfoliative cells from vaginal fornix that can self-operated with ease and comfort.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Agreement in the detection of high-risk HPV type in physician collected specimen and patient sampled specimen.
Time Frame: through study completion, an average of 1 year
|
Rate of the "agreement".
The "agreement" is defined as either (1) presence of any high-risk HPV type in physician collected specimen, and the patient sampled specimen, or (2) absence of high-risk HPV in physician collected specimen and the patient sampled specimen.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Agreement in HPV detection between physician collected sample and self-collected sample
Time Frame: through study completion, an average of 1 year
|
Rate of the "agreement".
The "agreement" is defined as either (1) presence of any HPV type in physician collected specimen, and the patient sampled specimen, or (2) absence of any HPV in physician collected specimen and the patient sampled specimen.
|
through study completion, an average of 1 year
|
Percentage of a valid specimen, according to the presence of the beta-globin gene in the self-collected specimen, and compares to the physician-collected specimen
Time Frame: through study completion, an average of 1 year
|
Percentage of the presence of the beta-globin gene.
The ratio could be calculated between self-collected and physician-collected specimens.
|
through study completion, an average of 1 year
|
Any adverse event resulted from collecting the specimen
Time Frame: within one month after sample collection
|
The number of participants with any adverse event.
|
within one month after sample collection
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hung-Hsueh Chou, MBBS, VS, Chang Gung Memorial Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HT19-HPV-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papillomavirus Infection
-
The AlfredMerck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection | Human PapillomavirusAustralia
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; American Cancer Society, Inc.; New... and other collaboratorsWithdrawnHuman Papillomavirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection
-
Sanford HealthCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedHuman Papillomavirus InfectionBahrain
-
Centre Hospitalier Universitaire de BesanconCompletedHuman Papillomavirus InfectionFrance
-
University Hospital, GenevaCompletedHuman Papillomavirus InfectionSwitzerland
-
University of ConnecticutCompletedHuman Papillomavirus Infection
-
Indiana UniversityMerck Sharp & Dohme LLCUnknownHuman Papillomavirus InfectionUnited States
-
Gen-Probe, IncorporatedCompletedHuman Papillomavirus InfectionUnited States
Clinical Trials on Self sampling kit for collecting discharge from vaginal fornix
-
University Hospital, ToursCompletedCervical Cancer | Human Papillomavirus Infection
-
University Hospitals Coventry and Warwickshire...Abbott; Copan Italia SPA , Via F. Perotti, 10, 25125 Brescia, ItalyWithdrawnCervix DiseasesUnited Kingdom
-
Universidade do PortoInstituto Portugues de Oncologia, Francisco Gentil, Porto; Unidade de Saúde... and other collaboratorsNot yet recruitingPapillomavirus Infections | Cervix Cancer | Early Detection of Cancer | Self-Examination
-
University Hospital, MontpellierPaul Valérie University Montpellier; Regional Center for Cancer Screening (CRCDC)... and other collaboratorsActive, not recruitingCervical Cancer | Human Papilloma Virus | Uterine Cervical DiseaseFrance